Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small cell lung cancer.

G E Goodman1, R B Livingston

  • 1Swedish Hospital Medical Center, Tumor Institute, Seattle, Washington.

Disease-A-Month : DM
|December 1, 1989
PubMed
Summary
This summary is machine-generated.

Small cell lung cancer (SCLC) shows improved survival with combination chemotherapy and radiotherapy, offering curative potential for some patients. This distinct subtype requires specific clinical evaluation and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016
Same author

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.

The pharmacogenomics journal·2013
Same author

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Stimulation of area 13 and skin temperature changes following its ablation.

Federation proceedings·2010
Same author

Ablation of area 13 in primates.

Federation proceedings·2010
Same author

Pathology in suddenly decompressed rats.

Federation proceedings·2010
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Lung cancer is a leading cause of cancer mortality in the US, with overall survival rates below 10%.
  • Small cell lung cancer (SCLC), a distinct subtype comprising 20% of cases, exhibits unique biologic behavior and therapeutic responsiveness compared to other lung cancers.
  • Historically, SCLC had a median survival of 3 months, but advancements have improved outcomes.

Purpose of the Study:

  • To describe the unique clinical aspects of SCLC.
  • To provide an overview of the current clinical approach and treatment of SCLC.
  • To differentiate SCLC from other histological lung cancer subtypes.

Main Methods:

  • Review of clinical data and treatment outcomes for SCLC.
  • Analysis of therapeutic responses to chemotherapy and radiotherapy.

Related Experiment Videos

  • Comparison of SCLC characteristics with other lung cancer subtypes.

    • Main Results:

    • Combination chemotherapy and radiotherapy have increased median survival for SCLC patients to 1-2 years.
    • Approximately 10% of limited-stage SCLC patients now survive longer than 2 years, indicating curative potential.
    • SCLC's propensity for early dissemination necessitates thorough staging for effective clinical management.

    Conclusions:

    • SCLC's sensitivity to chemotherapy and radiotherapy has led to multiple clinical trials evaluating combined treatment modalities.
    • Understanding SCLC's unique cell of origin and clinical behavior is crucial for optimizing patient care.
    • Current treatment strategies focus on combined drug and radiotherapy approaches for SCLC.